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Abstract
Background: Digital ulcers (DU) present a challenging complication in systemic sclerosis (SSc). The aim of this
study was to combine clinical characteristics and imaging methods to a composite score for the prediction of DU
in SSc patients.
Methods: Seventy-nine SSc patients received clinical examination, their patient history was taken and nailfold
capillaroscopy (NC), colour Doppler ultrasonography (CDUS) and fluorescence optical imaging (FOI) of the hands
were performed at baseline. Newly developed DU over a period of approximately 12 months were registered. We
used criteria with area under the curve (AUC) of at least 0.6 in regard to the development of these new DU to
create the score (CIP-DUS, clinical features, imaging, patient history—digital ulcer score).
Results: Twenty-nine percent of all SSc patients developed new DU during follow-up (48.1% diffuse, 18.4% limited
SSc). Based on the cross-validated (cv) AUC, a weight (cvAUC > 0.6 and ≤ 0.65: 1; cvAUC > 0.65 and ≤ 0.7: 2; cvAUC
> 0.7: 3) was assigned to each selected parameter. The performance of the final CIP-DUS was assessed with and
without the CDUS/FOI component. For the scleroderma patterns in NC, three points were appointed to late, two to
active and one point to early capillaroscopy pattern according to Cutolo et al. The CIP-DUS including the CDUS and
FOI parameters resulted in a good diagnostic performance (AUC after cross-validation: 0.83, 95%CI 0.74 to 0.92) and
was well calibrated (chi-square = 12.3, p = 0.58). The cut-off associated with the maximum of sensitivity and
specificity was estimated at ≥ 10 points resulting in a sensitivity of 100% and specificity of 74% for new DU during
follow-up. Excluding CDUS and FOI parameters leads to a non-statistically significant lower performance (AUC after
cross-validation: 0.81, 95%CI 0.72 to 0.91). However, including CDUS and FOI resulted in a better classification of
patients in respect to the outcome new DU in follow-up due to significantly better reclassification performance
(NRI = 62.1, p = 0.001) and discrimination improvement (IDI = 9.7, p = 0.01).
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Conclusion: A new score was introduced with the aim to predict digital ulcers. If applied correctly and with the
new imaging techniques proposed, all patients at risk of digital ulcers throughout 12 months could be identified.
Keywords: Systemic sclerosis, Capillaroscopy, Colour Doppler ultrasound, Fluorescence optical imaging, Modified
Rodnan skin score, Disturbed microcirculation, Digital ulcers
Background
Digital ulcers (DU) affect more than a third of patients
with systemic sclerosis (SSc) over time ensuing a consid-
erable decrease in quality of life [1]. Different risk factors
for the development of DU have already been described:
male gender, history of digital ulcers, pathologic CSURI
(Capillaroscopy Skin Ulcers Risk Index), and altered ESR
(erythrocyte sedimentation rate) [2]. So far, limited ef-
forts have been made to create a scoring system using
capillaroscopic findings. First, CSURI was developed,
which identifies patients at risk of developing new DU in
a 3-month follow-up [3–5]. However, a multicentre
study showed that 40% of their patients were not assess-
able with CSURI due to the absence of megacapillaries,
which are an essential part of the index’s equation [6].
Furthermore, Caramaschi et al. developed a score of risk
factors that was associated with ischemic digital ulcers
in SSc patients undergoing Iloprost treatment. They
identified four variables with high ORs for ischemic DU:
age at disease onset < 47.0 years (OR 6.17), delay in be-
ginning Iloprost therapy > 18 months (OR 5.70), history
of smoking (OR 6.80), and presence of contractures (OR
6.50). Thus, they designed an additive model with one
point per risk factor present. ROC analysis showed
promising results with an AUC of 0.836 (95% CI 0.736–
0.937) [7]. Manfredi et al. proposed a composite predict-
ive model including “capillaroscopic, demographic and
clinic-serological parameters” to identify patients at risk
for new digital ulcers [2].
In other rheumatologic diseases, the use of composite
scores is performed as a standard procedure, either to
assess disease activity or severity, e.g. SLAM (Systemic
Lupus Activity Measure), SLEDAI (Systemic Lupus Ery-
thematosus Disease Activity Index) or BILAG (British
Isles Lupus Assessment Group) for systemic lupus ery-
thematosus; and DAS28 (Disease activity score 28),
SDAI (simple disease activity index), and CDAI (clinical
disease activity index) for rheumatoid arthritis, and
many more in other indications such as psoriatic arth-
ritis or ankylosing spondylitis. Most of these composite
scores have been developed to reflect current disease ac-
tivity, but also in order to account the emergence of new
clinical manifestations of the underlying disease. Com-
posite scores in the field of rheumatology usually take
into account biomarkers or laboratory markers as well
as clinical findings and information given by patients.
So far, there has not yet been presented a composite
score created for patients with systemic sclerosis. Our
aim was to create a composite score for the prediction
of digital ulcers in SSc patients combining clinical data,
imaging, and patient history based on the results that
were recently published by our group [8].
Patients and methods
Seventy-nine in- and out-patients with SSc were re-
cruited. A signed informed consent was obtained from
all patients. Three patients dropped out during the
follow-up period: one patient withdrew her consent; two
patients unfortunately died. After a medium of 12
months, we asked for newly developed digital ulcers dur-
ing the follow-up period.
The included SSc patients received clinical examin-
ation, nailfold capillaroscopy (NC), colour Doppler ultra-
sonography (CDUS) [8, 9], and fluorescence optical
imaging (FOI) [8, 10] of both hands at baseline, and also
their patient history was taken as described in detail in
our previous publications [8–10]. The two examiners
were not blinded to patient history or clinical manifesta-
tions of the disease when performing the imaging tech-
niques. Furthermore, NC was performed to assess for
capillary density and capillaroscopy patterns (late, active,
and early) introduced by Cutolo et al. in the year 2000.
Statistical analyses
The association of each potential score component with
the likelihood of newly developed DU was estimated by
means of a logistic regression model. The area under
curve (AUC) was determined to assess the predictive
performance of each predictor variable. K-fold (k = 10)
cross-validation was used to evaluate the predictive per-
formance of each parameter to generate a more realistic
estimate of predictive performance [11]. The idea of
cross-validation is to randomly divide the data into k
equal-sized parts. The kth part is left out, the model is
fit to the other k − 1 parts, and then predictions for the
left-out kth part are obtained. A parameter was included
into the score if the resulting AUC reached a value of at
least 0.6. Based on the cross-validated (cv) AUC, a
weight (cvAUC > 0.6 and ≤ 0.65: 1; cvAUC > 0.65 and ≤
0.7: 2; cvAUC > 0.7: 3) was assigned to each selected
parameter. The performance of the final CIP-DUS was
assessed with and without the CDUS/FOI component.
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The improved model performance by adding the CDUS/
FOI component was evaluated by comparing the AUC
using the algorithm suggested by DeLong [12]. In
addition, the net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) [13] were
calculated to evaluate the appropriate or inappropriate
reclassification of patients after adding CDUS/FOI. Fi-
nally, the calibration of the logistic model was tested by
calculating Hosmer-Lemeshow chi-square test. Statistical
analyses were performed with STATA 12.1 (StataCorp.
2011. Stata Statistical Software: Release 12. College Sta-
tion, TX: StataCorp LP).
Results
Of the 76 SSc patients (62 female patients, n = 43 with
limited cutaneous SSc and n = 19 with diffuse cutaneous
SSC) that were questioned at 12 months follow-up, 29%
reported newly developed DU (48.1% of patients with
diffuse SSc and 18.4% of patients with limited SSc) (see
Supplementary Table and [8]). The obtained AUC were
calculated for potential parameters to be included in the
CIP-DUS after k-fold cross-validation. A strong associ-
ation with newly developed DU during follow-up was
observed for history of digital ulcer and/or pitting scars
(OR 36.2; 95% CI 2.1 to 626.9; AUC 0.77), present digital
ulcers and/or pitting scars at baseline (OR 15.7; 95%CI 3.3
to 74.3; AUC 0.76), and the NC pattern (OR 18.6; 95%CI
1.1 to 326.4; AUC 0.70). The modified Rodnan skin score
was moderately associated with the likelihood for newly
developed ulcers at follow-up. A weight of one was
assigned to the SSc subtype, pulmonary arterial hyperten-
sion, reduced capillary density (n < 7/mm) in digit III of
the right hand in NC, missing initial enhancement in FOI
in digit III of the right hand, and percentage of pathologic
(i.e. narrowed or occluded) vessels > 35% in CDUS based
on the AUC. For the scleroderma patterns in nailfold
capillaroscopy as introduced by Cutolo et al., three points
were appointed to late, two to active, and one to early
capillaroscopy pattern (see Table 1).
The CIP-DUS including the CDUS and FOI parameters
resulted in a good diagnostic performance (AUC after
cross-validation: 0.83, 95%CI 0.74 to 0.92, see Fig. 1) and
was well calibrated (chi-square = 12.3, p = 0.58). The cut-off
associated with the maximum of sensitivity and specificity
was estimated at ≥ 10 points resulting in a sensitivity of
100% and specificity of 74% for new DU during follow-up.
Alternatively, the score was calculated without inclu-
sion of the CDUS and FOI parameters. It resulted in a
slightly lower diagnostic performance (AUC after cross-
validation: 0.81, 95%CI 0.72 to 0.91) as compared to
CIP-DUS. The difference was not statistically significant
(chi-square = 1.6, p = 0.20, Fig. 1). But the inclusion of
CDUS and FOI resulted in a significantly better reclassi-
fication performance (NRI = 62.1, p = 0.001) and
discrimination improvement (IDI = 9.7, p = 0.01) in com-
parison to the score in absence of CDUS and FOI indi-
cating a better classification of patients in respect to the
outcome DU at follow-up. In more detail, 14 (64% of 22
patients with DU at follow-up) had a higher predicted
probability for a positive outcome by including CDUS
and FOI, whereas 18 patients (33% of 54 patients with-
out DU at follow-up) had a lower predicted probability
for a positive outcome. The other way around, only 4
patients (18%) were assigned to a lower risk and 9 pa-
tients (18%) to a higher risk in patients with and without
a DU at follow-up, respectively. It means that CIP-DUS
(including CDUS and FOI) tended to result in higher
predicted probabilities in patients with DU at follow-up
and lower predicted probabilities in patients without, in-
dicating a better diagnostic performance (sensitivity and
specificity).
Discussion
The aim of our project was to combine patient history,
clinical and imaging findings in order to create a com-
posite score able to determine the individual risk for the
development of new DU in SSc patients during a 12-
month follow-up. The odds ratios of known risk factors
and other features were obtained.
Consistent with previous literature, current or previous
digital ulcers and/or pitting scars were important factors
in the recurrence of this complication [2, 14]. Our data
also suggest a link between skin involvement (represented
by a diffuse cutaneous subtype or a high mRSS) and the
DU development [8]. Sunderkötter et al. [14] also found
that a diffuse skin sclerosis significantly impacted on the
appearance of DU in multivariate analysis, but only when
pulmonary arterial hypertension was present. Here, in uni-
variate analysis, both the diffuse subtype and pulmonary
arterial hypertension (PAH) were associated with digital
ulcers in a 12-month follow-up.
While PAH as a sign of systemic vasculopathy already
links to the pathophysiology of digital ulcers, the evi-
dence of micro- and macrovasculopathy in imaging is an
established tool in the diagnostic and risk stratification
of SSc patients. In accordance with our results, Smith
et al. [15] found a more severe capillaroscopic pattern
predictive for future severe peripheral vascular involve-
ment. In the CAP study, the mean number of capillaries
per millimetre in the middle finger of the dominant
hand was identified as one of the strongest risk factors
for new DU [16]. This is comparable with our finding
that a reduced capillary density in the right middle finger
indicated a higher risk of ulcers. Interestingly, pathologic
findings in this finger detected by FOI and CDUS (not
significant) were also associated with our primary end
point. In CDUS however, an overall high percentage of
pathologic vessels showed better predictive values.
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While the single identified risk factors showed either
low sensitivity (skin involvement, CDUS, FOI) or low
specificity (DU presence/history, capillaroscopy) levels
(data not shown), we aimed to combine the factors to a
predictive score. The final composite score proved good
diagnostic performance with perfect sensitivity of 100%
and good specificity of 74% at a cut-off of ≥ 10 points.
Excluding the uncommon imaging techniques CDUS
and FOI, the score showed a slightly lower diagnostic
performance in comparison to the complete CIP-DUS,
which was not statistically significant. However, reclassi-
fication performance and discrimination improvement
were significantly better when the full CIP-DUS (includ-
ing CDUS and FOI) was assessed.
One limitation of the proposed CIP-DUS is the limited
availability of the suggested imaging methods CDUS and
FOI. Nevertheless, our data revealed an only slight de-
crease of the score’s performance when excluding those
two imaging methods. This shows that with the com-
monly obtained information (clinical data, NC, patient
history), which every clinician treating SSc patients
should possess, a practical and powerful score assess-
ment of the risk to develop new DU is still possible and
should be integrated in clinical routine.
The assessment of DU is a challenging task. Occur-
rence of DU during follow-up was assessed via a tele-
phone or personal interview and patients were
instructed (using pictures) at baseline to look out for
and document newly formed ulcers on their hands in
order to improve accuracy at follow-up. A limitation of
this study is the insufficient differentiation made be-
tween ischemic and traumatic ulcers.
Advantages of this study include the relatively long
follow-up period of 12 months and the thorough character-
isation of the patients including demographic, clinical,
laboratory, and imaging data. Due to the complex patho-
physiology of systemic sclerosis and its complications such
as DU, taking all these factors into account is paramount
when trying to reduce the risk of DU in the future.
As this is a pilot project, the predictive values of
the composite score have unfortunately not yet been
applied on an independent cohort. This should be
conducted in future studies on a larger scale of pa-
tients—if only in the reduced form without FOI and
CDUS. Even the reduced CIP-DUS, which integrates
the usually present patient information about clinical
presentation, patient history as well as NC pattern
and capillary density can provide a powerful risk as-
sessment for future DU in SSc patients.
Conclusions
The new composite score CIP-DUS predicts digital
ulcer development throughout a 12-month follow-up
and identifies all “at risk” patients. Even without the
new imaging features, which might not be available to
all clinicians, the score still shows good performance
in regard to detecting patients at risk for new DU
development.
Fig. 1 Receiver operating characteristic (ROC) of the CIP-DUS and the score in absence of CDUS and FOI regarding the development of new
digital ulcers in a 12-month follow-up
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-02235-7.
Additional file 1:. Supplement Table. Baseline patient characteristics,
including diagnosis, sex, age (±SD), Raynaud’s phenomenon, digital ulcers
and nailfold capillaroscopy patterns as described by Cutolo et al. (table
cited from [8]).
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